Skip to main content
PYXS
NASDAQ Life Sciences

GordonMD Group Invests $12.2M in Pyxis Oncology's $110M Offering

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.21
Mkt Cap
$182.664M
52W Low
$1.03
52W High
$5.55
52W Position info
115% above low
Off High info
60% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

PYXS has more than doubled off its 52-week low of $1.03 on elevated volume (2.1× avg).

Summary

GordonMD entities invested $12.2 million in Pyxis Oncology's $110 million offering, acquiring 13.06 million shares and 7.55 million warrants at $2.90 per unit.


Key Events · Ownership and Investor Activity · PYXS

  • GordonMD Invests $12.2M in Offering

    GordonMD Global Investments and affiliates acquired 13,063,766 shares and 7,546,766 warrants at $2.90 per unit, totaling $12.19 million.

  • Stake Rises to 15.5M Shares

    Post-transaction holdings reach 15,541,909 shares, consolidating the group's position as a major shareholder.

  • Warrants Contingent on Charter Amendment

    The 7.55 million warrants carry a $3.50 exercise price and cannot be exercised until shareholders approve an increase in authorized shares.

  • Follows $110M Offering Close

    The purchase occurred on October 1, 2026, the same day Pyxis Oncology closed its $110 million public offering with $102.8 million in net proceeds.


Analysis · PYXS · Life Sciences

GordonMD Global Investments and affiliated entities acquired 13.06 million shares and 7.55 million warrants in Pyxis Oncology's public offering, a $12.2 million commitment from the company's largest shareholder group. The purchase comes one day after the offering closed, extending the group's stake to 15.5 million shares. The warrants carry a $3.50 exercise price and are contingent on shareholder approval of a charter amendment to increase authorized shares — a condition that could create near-term overhang if approved.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PYXS was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $182.7M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PYXS - Latest Insights

PYXS
Nov 19, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $1.69 info
Change: +$0.190 (+13%) info
Market Cap: $200.941M info
PYXS
Nov 18, 2026, 6:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $1.69 info
Change: +$0.230 (+16%) info
Market Cap: $200.941M info
PYXS
Nov 13, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $1.69 info
Change: +$0.110 (+7%) info
Market Cap: $200.941M info
PYXS
Nov 05, 2026, 7:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.65
Real-time Price: $1.69 info
Change: +$0.040 (+2%) info
Market Cap: $200.941M info
PYXS
Nov 05, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.65
Real-time Price: $1.69 info
Change: +$0.040 (+2%) info
Market Cap: $200.941M info